In PSP, most studies demonstrate 18F-flortaucipir retention correlating with areas of predicted tau neuropathology, differentiating PSP patients from normal subjects and patients with Alzheimer’s or Parkinson’s disease at a group level, though negative results have also been reported [24–28]. Here, MAPT is linked to supranuclear palsy, progressive, 1.